Literature DB >> 7826125

Audit of guidelines for effective control of chemotherapy and radiotherapy induced emesis.

A B Foot1, C Hayes.   

Abstract

A system was devised to establish the optimum treatment for emesis for each individual child receiving cytotoxic treatment. Cytotoxic drugs were ranked on a scale (1-5), with antiemetic regimens correspondingly graded. An age division (< or = 5 years, > 5 years) was included. Cytotoxic treatment was given with co-administration of the parallel antiemetic regimen. Failure to control emesis required administration of a stronger regimen as defined in the guidelines. A prospective clinical audit was performed to monitor the efficacy and utility of the system using diary cards to record episodes of nausea or vomiting, or both, completed by the patient or a parent and the nursing staff. The following audit criteria were set: (a) 80% control with first courses of chemotherapy; (b) 85% control with subsequent courses of similar chemotherapy; and (c) 90% lack of anticipatory nausea. Sixty children (< 18 years) received emetogenic cytotoxic drugs from February-June 1993. The criteria were satisfied in two of three categories, with 82% control for first courses of chemotherapy, 83% control for subsequent courses of chemotherapy, and 90% lack of anticipatory nausea. The guidelines were workable and acceptable overall. Minor modifications have been made subsequent to the audit to improve their efficacy further.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7826125      PMCID: PMC1030071          DOI: 10.1136/adc.71.5.475

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  8 in total

1.  A survey of antiemetic use in children with cancer.

Authors:  J van Hoff; M J Hockenberry-Eaton; K Patterson; J J Hutter
Journal:  Am J Dis Child       Date:  1991-07

2.  Methylprednisolone for chemotherapy-induced emesis: a double-blind randomized trial in children.

Authors:  P Mehta; S Gross; J Graham-Pole; R Gardner
Journal:  J Pediatr       Date:  1986-05       Impact factor: 4.406

3.  Side effects of metoclopramide as an antiemetic in childhood cancer chemotherapy.

Authors:  B N Terrin; N B McWilliams; H M Maurer
Journal:  J Pediatr       Date:  1984-01       Impact factor: 4.406

4.  Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy.

Authors:  D B Smith; E S Newlands; G J Rustin; R H Begent; N Howells; B McQuade; K D Bagshawe
Journal:  Lancet       Date:  1991-08-24       Impact factor: 79.321

5.  5-HT3 antagonist ondansetron--an effective outpatient antiemetic in cancer treatment.

Authors:  C R Pinkerton; D Williams; C Wootton; S T Meller; T J McElwain
Journal:  Arch Dis Child       Date:  1990-08       Impact factor: 3.791

Review 6.  Control of chemotherapy-induced emesis.

Authors:  S M Grunberg; P J Hesketh
Journal:  N Engl J Med       Date:  1993-12-09       Impact factor: 91.245

7.  Metoclopramide: dose-related toxicity and preliminary antiemetic studies in children receiving cancer chemotherapy.

Authors:  J C Allen; R Gralla; L Reilly; M Kellick; C Young
Journal:  J Clin Oncol       Date:  1985-08       Impact factor: 44.544

8.  Effective emetic control during conditioning of children for bone marrow transplantation using ondansetron, a 5-HT3 antagonist.

Authors:  M Hewitt; J Cornish; D Pamphilon; A Oakhill
Journal:  Bone Marrow Transplant       Date:  1991-06       Impact factor: 5.483

  8 in total
  7 in total

1.  Corticosteroids in the management of central nervous system tumours. Kids Neuro-Oncology Workshop (KNOWS).

Authors:  A W Glaser; N Buxton; D Walker
Journal:  Arch Dis Child       Date:  1997-01       Impact factor: 3.791

Review 2.  Granisetron. A pharmacoeconomic evaluation of its use in the prophylaxis of chemotherapy-induced nausea and vomiting.

Authors:  G L Plosker; P Benfield
Journal:  Pharmacoeconomics       Date:  1996-04       Impact factor: 4.981

3.  Cost-effectiveness analysis of tropisetron vs. chlorpromazine-dexamethasone in the control of acute emesis induced by highly emetogenic chemotherapy in children.

Authors:  I Tejedor; A Idoate; M Jiménez; L Sierrasesumaga; J Giráldez
Journal:  Pharm World Sci       Date:  1999-04

Review 4.  Nausea and vomiting associated with cancer chemotherapy: drug management in theory and in practice.

Authors:  E S Antonarakis; R D W Hain
Journal:  Arch Dis Child       Date:  2004-09       Impact factor: 3.791

Review 5.  Options for the prevention and management of acute chemotherapy-induced nausea and vomiting in children.

Authors:  L Lee Dupuis; Paul C Nathan
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

Review 6.  Antiemetic medication for prevention and treatment of chemotherapy-induced nausea and vomiting in childhood.

Authors:  Robert S Phillips; Amanda J Friend; Faith Gibson; Elizabeth Houghton; Shireen Gopaul; Jean V Craig; Barry Pizer
Journal:  Cochrane Database Syst Rev       Date:  2016-02-02

7.  An overview of the clinical use of ondansetron in preschool age children.

Authors:  Ira Todd Cohen
Journal:  Ther Clin Risk Manag       Date:  2007-06       Impact factor: 2.423

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.